vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and AVANOS MEDICAL, INC. (AVNS). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $180.9M, roughly 1.0× AVANOS MEDICAL, INC.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -0.7%, a 14.1% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $21.3M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
AMPH vs AVNS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $180.9M |
| Net Profit | $24.4M | $-1.3M |
| Gross Margin | 46.8% | 47.5% |
| Operating Margin | 19.4% | 1.4% |
| Net Margin | 13.3% | -0.7% |
| Revenue YoY | -1.8% | 0.7% |
| Net Profit YoY | -35.7% | 99.7% |
| EPS (diluted) | $0.51 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $180.9M | ||
| Q3 25 | $191.8M | $177.8M | ||
| Q2 25 | $174.4M | $175.0M | ||
| Q1 25 | $170.5M | $167.5M | ||
| Q4 24 | $186.5M | $179.6M | ||
| Q3 24 | $191.2M | $170.4M | ||
| Q2 24 | $182.4M | $171.7M | ||
| Q1 24 | $171.8M | $166.1M |
| Q4 25 | $24.4M | $-1.3M | ||
| Q3 25 | $17.4M | $-1.4M | ||
| Q2 25 | $31.0M | $-76.8M | ||
| Q1 25 | $25.3M | $6.6M | ||
| Q4 24 | $38.0M | $-397.3M | ||
| Q3 24 | $40.4M | $4.3M | ||
| Q2 24 | $37.9M | $1.8M | ||
| Q1 24 | $43.2M | $-900.0K |
| Q4 25 | 46.8% | 47.5% | ||
| Q3 25 | 51.4% | 48.4% | ||
| Q2 25 | 49.6% | 52.6% | ||
| Q1 25 | 50.0% | 53.6% | ||
| Q4 24 | 46.5% | 54.6% | ||
| Q3 24 | 53.3% | 54.5% | ||
| Q2 24 | 52.2% | 55.7% | ||
| Q1 24 | 52.4% | 57.1% |
| Q4 25 | 19.4% | 1.4% | ||
| Q3 25 | 13.2% | 0.1% | ||
| Q2 25 | 24.2% | -42.6% | ||
| Q1 25 | 21.9% | 6.1% | ||
| Q4 24 | 24.2% | -233.0% | ||
| Q3 24 | 29.8% | 7.0% | ||
| Q2 24 | 30.3% | 3.7% | ||
| Q1 24 | 27.9% | 2.4% |
| Q4 25 | 13.3% | -0.7% | ||
| Q3 25 | 9.0% | -0.8% | ||
| Q2 25 | 17.8% | -43.9% | ||
| Q1 25 | 14.8% | 3.9% | ||
| Q4 24 | 20.4% | -221.2% | ||
| Q3 24 | 21.1% | 2.5% | ||
| Q2 24 | 20.8% | 1.0% | ||
| Q1 24 | 25.1% | -0.5% |
| Q4 25 | $0.51 | $-0.02 | ||
| Q3 25 | $0.37 | $-0.03 | ||
| Q2 25 | $0.64 | $-1.66 | ||
| Q1 25 | $0.51 | $0.14 | ||
| Q4 24 | $0.74 | $-8.64 | ||
| Q3 24 | $0.78 | $0.09 | ||
| Q2 24 | $0.73 | $0.04 | ||
| Q1 24 | $0.81 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $89.8M |
| Total DebtLower is stronger | $608.7M | $90.3M |
| Stockholders' EquityBook value | $788.8M | $778.2M |
| Total Assets | $1.6B | $1.1B |
| Debt / EquityLower = less leverage | 0.77× | 0.12× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $89.8M | ||
| Q3 25 | $276.2M | $70.5M | ||
| Q2 25 | $231.8M | $90.3M | ||
| Q1 25 | $236.9M | $97.0M | ||
| Q4 24 | $221.6M | $107.7M | ||
| Q3 24 | $250.5M | $89.0M | ||
| Q2 24 | $217.8M | $92.2M | ||
| Q1 24 | $289.6M | $75.8M |
| Q4 25 | $608.7M | $90.3M | ||
| Q3 25 | $608.6M | $93.4M | ||
| Q2 25 | $607.7M | $95.7M | ||
| Q1 25 | $603.9M | $98.0M | ||
| Q4 24 | $601.6M | $125.3M | ||
| Q3 24 | $596.4M | $152.6M | ||
| Q2 24 | $586.9M | $164.9M | ||
| Q1 24 | $594.0M | $167.2M |
| Q4 25 | $788.8M | $778.2M | ||
| Q3 25 | $776.7M | $778.0M | ||
| Q2 25 | $757.5M | $776.3M | ||
| Q1 25 | $751.3M | $839.4M | ||
| Q4 24 | $732.3M | $828.5M | ||
| Q3 24 | $727.7M | $1.2B | ||
| Q2 24 | $713.3M | $1.2B | ||
| Q1 24 | $672.4M | $1.2B |
| Q4 25 | $1.6B | $1.1B | ||
| Q3 25 | $1.7B | $1.1B | ||
| Q2 25 | $1.6B | $1.0B | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.5B | $1.7B | ||
| Q2 24 | $1.5B | $1.7B | ||
| Q1 24 | $1.6B | $1.7B |
| Q4 25 | 0.77× | 0.12× | ||
| Q3 25 | 0.78× | 0.12× | ||
| Q2 25 | 0.80× | 0.12× | ||
| Q1 25 | 0.80× | 0.12× | ||
| Q4 24 | 0.82× | 0.15× | ||
| Q3 24 | 0.82× | 0.12× | ||
| Q2 24 | 0.82× | 0.13× | ||
| Q1 24 | 0.88× | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $28.2M |
| Free Cash FlowOCF − Capex | $24.6M | $21.3M |
| FCF MarginFCF / Revenue | 13.4% | 11.8% |
| Capex IntensityCapex / Revenue | 4.5% | 3.8% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $43.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $28.2M | ||
| Q3 25 | $52.6M | $14.0M | ||
| Q2 25 | $35.6M | $6.8M | ||
| Q1 25 | $35.1M | $25.7M | ||
| Q4 24 | $29.0M | $57.9M | ||
| Q3 24 | $60.0M | $23.0M | ||
| Q2 24 | $69.1M | $27.8M | ||
| Q1 24 | $55.3M | $-8.0M |
| Q4 25 | $24.6M | $21.3M | ||
| Q3 25 | $47.2M | $7.0M | ||
| Q2 25 | $25.0M | $-4.2M | ||
| Q1 25 | $24.4M | $19.0M | ||
| Q4 24 | $16.6M | $53.1M | ||
| Q3 24 | $46.2M | $20.0M | ||
| Q2 24 | $63.1M | $21.9M | ||
| Q1 24 | $46.5M | $-12.1M |
| Q4 25 | 13.4% | 11.8% | ||
| Q3 25 | 24.6% | 3.9% | ||
| Q2 25 | 14.3% | -2.4% | ||
| Q1 25 | 14.3% | 11.3% | ||
| Q4 24 | 8.9% | 29.6% | ||
| Q3 24 | 24.1% | 11.7% | ||
| Q2 24 | 34.6% | 12.8% | ||
| Q1 24 | 27.1% | -7.3% |
| Q4 25 | 4.5% | 3.8% | ||
| Q3 25 | 2.8% | 3.9% | ||
| Q2 25 | 6.1% | 6.3% | ||
| Q1 25 | 6.3% | 4.0% | ||
| Q4 24 | 6.7% | 2.7% | ||
| Q3 24 | 7.2% | 1.8% | ||
| Q2 24 | 3.3% | 3.4% | ||
| Q1 24 | 5.1% | 2.5% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | 3.89× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 5.35× | ||
| Q2 24 | 1.82× | 15.44× | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
